SYSTEMATIC REVIEW

Predictive value of pre-treatment FDG PET in patients with non-Hodgkin lymphoma treated with radioimmunotherapy: a systematic review

Silvia Morbelli[1,2] · Selene Capitanio[1,2] · Luca Guerra[3] · Luigi Rigacci[4]

Abstract

Purpose We aimed to systematically review studies addressing the value of baseline FDG PET as predictive biomarker for response to RIT in patients with NHL.

Methods We searched (last update: March 2019) the databases PubMed, PMC, Google Scholar and Medline using both as text and as MeSH (Medical Subject Headings) terms the following: "positron emission tomography—PET", "PET/CT", "FDG", "^{18}F-fluorodeoxyglucose", and "radioimmunotherapy", "^{90}Y-ibritumomab tiuxetan" and "non-Hodgkin lymphoma" and "follicular lymphoma". Among all the retrieved articles, we selected only those specifically analyzing role, predictive and overall value of pretreatment FDG PET in patients with NHL submitted to RIT.

Results The initial search retrieved seventy articles, however, only eight specifically analyzed the predictive value of pretreatment FDG PET in patients with NHL submitted to RIT and were thus discussed. Eight studies in 254 patients evaluated the role of FDG PET as a predictor of response prior to RIT. Despite several methodological issues, patients- and lesion-based analyses carried out to-date seem to suggest a relevant prognostic role of both morphological computed tomography and metabolic imaging.

Conclusions Although it is still not possible to specifically define the best PET-based predictor (i.e. SUVmax, TLG, MTV), FDG-PET is a promising tool for a more accurate and individualized selection of NHL patients candidates to RIT. The availability of FDG PET examinations in homogenous group of patients included in already completed clinical trials might be used in the next future also to specifically assess the prognostic value of baseline FDG PET in patients treated with RIT based on the study design.

Keywords Positron emission tomography · ^{18}F-FDG · Radioimmunotherapy · ^{90}Y-ibritumomab tiuxetan

✉ Silvia Morbelli
silvia.morbelli@unige.it

1 Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

2 Nuclear Medicine Unit, Department of Health Sciences, University of Genoa, Genoa, Italy

3 Nuclear Medicine Unit, San Gerardo Hospital, Monza, Italy

4 UO Ematologia e Centro Trapianti Cellule Staminali, AO San Camillo Forlanini, Rome, Italy

Introduction

Radioimmunotherapy (RIT) involves monoclonal antibodies (mAb) to selectively target the surface antigens on malignant cells, and a radioisotope coupled to the mAb, which selectively delivers ionizing radiation to the tumor [1]. Ibritumomab tiuxetan (Zevalin®; Spectrum Pharmaceuticals, Irvine, CA) is a murine antiCD20 monoclonal antibody conjugated to Yttrium-90 (^{90}Y-IT). It is currently the only available RIT drug approved in Europe and in the United States for the treatment of patients with lymphoma specifically for the treatment of relapsed or refractory, low-grade or follicular B-cell NHL as well as for previously untreated follicular lymphoma (FL) in patients who achieve a partial or complete response to first-line chemotherapy [2, 3]. Approved indications for ^{90}Y-IT followed the publications of the results

of several clinical trials demonstrating that in patients with relapsed and/or refractory low-grade NHL, a single dose of ^{90}Y-IT induces overall response rates in 70–80% and a complete response in 15–50% of patients [3–6].

In more recent years several authors investigated the usefulness of ^{90}Y-IT either as consolidation treatment after immunochemotherapy or as monotherapy in first line [7, 8]. These studies suggested that RIT might induce a more profound response, postponing an eventual relapse when used as consolidation after induction immunochemotherapy [7]. However, almost all patients nowadays receive rituximab in first line. Accordingly, ^{90}Y-IT is considered a potential treatment option especially in patients with FL who are not eligible for rituximab maintenance [9]. The efficacy of RIT in other types of NHL has also been tested. Available studies demonstrated durable and feasible responses in an extended variety of NHL types and patient populations [10–14]. On the other side, the most common adverse reactions of ^{90}Y-IT are cytopenias, fatigue, nasopharyngitis, nausea, abdominal pain, asthenia, cough, diarrhea, and pyrexia, while the most serious adverse reactions are prolonged and severe cytopenias (thrombocytopenia, anemia, lymphopenia, neutropenia). However, the presence of grade 4 neutropenia or thrombocytopenia has been demonstrated respectively in around 30% and 10% of patients enrolled in clinical trials [3]. Despite the evidence that RIT positively affects NHL patients' outcomes without compromising the quality of life, use of RIT remains limited [15, 16]. Potential issues associated with underuse of RIT are related to inadequate reimbursement policies, lack of widespread availability, concerns about radiation protection issues and about potential delayed toxicities (e.g., marrow damage, secondary malignancies and treatment-related myelodysplastic syndromes), which actually are rare in clinical practice [16–18]. Similarly, despite several studies there's still lack of evidence-based parameters which can predict the response to RIT on an individual patient basis [19].

Indeed, type of lymphoma (indolent versus non-indolent subtypes), serum levels of lactate dehydrogenase (LDH) and βeta-2 microglobulin (β2M), disease extension, age, previous therapies, molecular markers, body surface area (BSA) and more in general clinical prognostic indexes such as Follicular Lymphoma International Prognostic Index (FLIPI) and International Prognostic Index (IPI) have been taken into account as potential predictors of response to RIT [19]. However, the prognostic role of several of these biomarkers is still controversial. Similarly, imaging studies have tried to address the same issues. In this framework, acquisition of a pretreatment ^{111}In-ibritumomab tiuxetan scan has been historically used as a method for measuring organ-specific accumulation of ibritumomab tiuxetan and it was also tested for RIT efficacy prediction [20–22]. Despite the obvious relevance of organ-specific accumulation of ibritumomab

tiuxetan, previous studies concluded that there's no clear evidence about a relationship between the intensity of uptake at a disease site on the pre-RIT ^{111}In-ibritumomab tiuxetan scan and response to treatment. In recent years the value of pretreatment FDG PET scan to predict RIT efficacy has also been tested. In this context, several different semiquantitative measures might be taken into account when assessing the predicting value of FDG PET, and thus comparability of results of different studies might be not always straightforward [19]. Accordingly, while several studies have suggested a potential role FDG PET in evaluating response to RIT [23–25], the prognostic role of FDG PET before RIT is still considered controversial [19]. In the present systematic review, we thus aimed to summarize and discuss studies addressing the value of baseline FDG PET as predictive biomarker for response to RIT in patients with NHL. As a matter of fact, only an effective and more individualized risk stratification can lead to a clear understanding and a better selection of patients considered candidates for RIT thus allowing to optimize the efficacy and safety of treatment with RIT [26].

Evidence acquisition

We searched (last update: March 2019) the databases Pub-Med, PMC, Google Scholar and Medline using both as text and as MeSH (Medical Subject Headings) terms the following: "positron emission tomography—PET", "PET/CT", "FDG", "^{18}F-fluorodeoxyglucose", and "radioimmunotherapy", '^{90}Y-ibritumomab tiuxetan' and "non-Hodgkin lymphoma" and "follicular Lymphoma". We also included additional studies if cited in the selected articles. No language restriction was applied to the search, but the reviewed articles were all in English. Among all the retrieved articles, we selected only those specifically analyzing role, predictive and overall value of pretreatment FDG PET in patients with NHL submitted to RIT. A total of eight papers met the inclusion criteria and were selected [22, 27–33]. Characteristic of selected studies are summarized in Table 1.

Evidence synthesis

We will synthesize findings in the literature by focusing on studies involving the use of pretreatment FDG PET as predictor of response in NHL patients treated with RIT trying to focus both on the added value of FDG PET examination and on the predictive value of different semiquantitative biomarkers such as maximum and mean standardized uptake values (SUVmax, and SUVmean), metabolic tumor volume (MTV), Total lesion Glycolysis (TLG). We will also comment the potential role of more sophisticated approaches able to capture metabolic heterogeneity within NHL lesions

Table 1 Studies evaluating the prognostic role of baseline FDG PET in patients treated with radioimmunotherapy

Reference	Sample	Study type	Lymphoma type (WHO classification)	Clinical scenario at the time of PET	RIT	Semiquantitative measures	Other prognostic biomarkers	Results
Hanaoka et al. [22]	16	Retrospective	CD20-positive B-cell non-Hodgkin FL	Pretherapeutic PET/CT. Ann Arbor stages 1, 2, 3, and 4 were 4, 2, 5, and 5, respectively. At least 1 cm lymphoma lesion analyzable on images as a target lesion	^{90}Y-ibritumomab tiuxetan	1. SUVmax 2. The skewness 3. Kurtosis of the voxel distribution were calculated to evaluate the intratumoral heterogeneity of tumor accumulation 4. Cumulative SUV-volume histograms	Pretherapeutic ^{111}In-ibritumomab tiuxetan SPECT/CT along with whole-body planar scans (1) SPECT/CT images percentage of the injected dose per gram (%ID/g) and SUVmax of ^{111}In-ibritumomab tiuxetan measured at 48 h after administration. (2) All lesions ($n = 42$) were classified into responders and non-responders lesion-by-lesion on pre- and post-therapeutic CT images	Positive correlation between FDG SUVmax and accumulation of ^{111}In-ibritumomab tiuxetan in lesions. Significant difference in pretherapeutic FDG SUVmax between responders and non-responders; no significant difference in ^{111}In-ibritumomab tiuxetan SUVmax between the two groups. Voxel distribution of FDG: no significant differences in the three heterogeneity indices between responders and non-responders
Tsukamoto et al. [27]	34	Retrospective	Indolent lymphoma (n. 27 FL grade 1–2; n. 5 FL grade 3a, n. 1 MALT, n. 1 MCL)	PET performed just before and at 8–12 weeks after ^{90}Y-IT treatment. Patients submitted to one (at least) or two-five prior regimens of therapy. Disease stage I–II/III–IV (17/17)	^{90}Y-ibritumomab tiuxetan	SUVmax	Tumor diameter of long axis, number of nodal sites at contrast-enhanced CT	PFS and OS were 32 months and not reached, respectively. In univariate analysis, tumor long-axis diameter ≤2.5 cm, SUVmax ≤6.5, localized disease, normal levels of serum soluble interleukin-2 receptor, and the number of involved nodal sites ≤3 immediately prior to RIT were associated with median PFS greater than 6 years. In multivariate analysis, only tumor long-axis diameter ≤2.5 cm and SUVmax ≤6.5 affected PFS

Table 1 (continued)

Reference	Sample	Study type	Lymphoma type (WHO classification)	Clinical scenario at the time of PET	RIT	Semiquantitative measures	Other prognostic biomarkers	Results
Hertzberg et al. [28]	143[a]	Prospective	High-risk DLBCL	Baseline PET prior to receiving 4 cycles of dose-dense R-CHOP-14, Interim PET at day 17–20 of cycle 4. 79% stages 3–4, 54% bulk, ECOG PS 0-3, high-risk DLBCL (either IPI 2–5 or 0-1 with bulk > 7.5 cm) previously untreated, considered fit for ASCT, with a positive baseline PET scan with more than one FDG-avid lesion with more than one FDG-avid lesion. 42/143 (29%) patients undergoing interim PET were positive (32 of whom completed R-ICE and 90Y-ibritumomab tiuxetan BEAM)	90Y-ibritumomab tiuxetan-BEAM	Deauville score	B symptoms, stage 3–4 disease, age over 60 years, ECOG PS over 1, BM involvement	At a median follow up of 35 months, the 2-year progression free survival for PET-positive patients was 67%, a rate similar to that for PET-negative patients treated with R-CHOP-14 (74%, $p = 0.11$); overall survival was 78% and 88% ($p = 0.11$), respectively. In an exploratory analysis, PSF and OS were markedly superior for PET positive Deauville score 4 versus score 5 ($p = 0.0002$ and $p = 0.001$, respectively). Therefore, diffuse large B-cell lymphoma patients who are PET-positive after 4 cycles of R-CHOP-14 and who switched to R-ICE and 90Y-ibritumomab tiuxetan-BEAM achieved favorable survival outcomes similar to those for PET-negative R-CHOP14-treated patients
Grgic et al. [29]	16	Retrospective (multicenter)	CD20-positive B-cell non-Hodgkin FL	PET performed just before RIT. Recurring or refractory CD20-positive B-cell non-Hodgkin FL. Most of the patients previously had underwent multiple chemotherapies and/ or radiotherapies. 6 received RIT as 2nd line therapy, 4 as 3rd line therapy, in 3 patients RIT was performed as 4th line therapy. 2 had received RIT as 5th line therapy and 1 patient had RIT as 6th line therapy	90Y-ibritumomab tiuxetan	1. SUVmax 2. Metabolic volume VOI method using 50% isocontour technique	CT lesion volume $= 4/3p \times$ radius $(r)1 \times r2 \times r3$	In the multivariate model the log lesion volume ($p < 0.0001$), the total ($p = 0.03$) and maximum lesion volume ($p = 0.05$) were predictors for response (CR + PR). Concerning the lesional CR initial small lesion volume ($p = 0.009$) and its high metabolic activity ($p = 0.01$) were identified as predictors. For complete response both SUVmax and log lesion volume were significant predictors. Lesion level response (PR + CR) was predominantly predicted by PET-volume

Table 1 (continued)

Reference	Sample	Study type	Lymphoma type (WHO classification)	Clinical scenario at the time of PET	RIT	Semiquantitative measures	Other prognostic biomarkers	Results
Lopci et al. [30]	59	Retrospective (multicenter)	CD20-positive B-cell non-Hodgkin FL	Baseline PET and second scan 3 months after RIT (range 9–18 weeks). Relapsed or refractory FL patients	^{90}Y-ibritumomab tiuxetan	SUVmax and SUVbw max	Individual prognostic factors (age, gender, time from diagnosis to RIT, number of previous treatments, disease extent before Zevalin, SUVbw max at baseline, and response to treatment)	A cut-off a SUVbw max = 6 was able to differentiate patients with longer PFS (SUVmax < 6, n = 14) with a projected 3-year PFS of 49% versus 13%, respectively (p = 0.038) (patients with SUVmax ≥ 6, n = 45). There were no differences (p = 0.3) in PFS between heavily pretreated patients (i.e. number of previous lines of therapy more than two) (n = 26) and patients who had had two or less previous treatments (n = 33). CR (post-RIT PET negative) (n = 27) had a significantly higher PFS, compared with PET-positive (PR, SD or PD) patients (n = 32), with a projected 3-year PFS of 40% versus 10%, respectively (p < 0.00001)
Lopci et al. [31]	38	Retrospective	CD20-positive B-cell non-Hodgkin FL	PET just before and three months after RIT. At baseline PET scan 20 patients out of 38 had a limited disease (nodal involvement on one side of the diaphragm: 7 above and 13 below), 11 patients had nodal findings on both sides of the diaphragm and the remaining 7 patients had both nodal and extra-nodal findings	^{90}Y-ibritumomab tiuxetan	No semiquantitive measures. Limited versus non-limited and extranodal disease according to baseline PET	–	FDG PET scan revealed maximal predictive values. When comparing the disease extent at relapse and the response to treatment, higher rate of CR was highlighted (75%) in patients with limited disease, while in patients with diffused nodal and/or extra-nodal findings, it was more frequent a PR or PD (66%)

Table 1 (continued)

Reference	Sample	Study type	Lymphoma type (WHO classification)	Clinical scenario at the time of PET	RIT	Semiquantitative measures	Other prognostic biomarkers	Results
Cazaentre et al. [32]	35	Retrospective	B-cell non-Hodgkin lymphoma (DLBCL 15, FL12, MALT2, MCL6)	PET prior to RIT	^{90}Y-ibritumomab tiuxetan (group A; $n = 17$) or (90) Y-epratuzumab tetraxetan (group B; $n = 18$)	SUVmax, SUVmean, functional LVol and TLG as product of the volume and the SUVmean. For each patient, highest SUVmax and SUVmean TLGcum and TVol was also determined	Conventional clinical and biochemical prognostic factors at diagnosis in responder vs. non-responder	154 lesions were analysed. Nineteen patients (54%) responded to RIT according to IWC. In group A, response rate was 54 in patients with a SUVmax <20 g/ml and 75% patients with either a TVol <100 ml and a TLGcum <1060 g, respectively while no patient above these thresholds responded (p < 0.005). In group B, the response rate was 93% for with SUVmax <15 g/ml while no patient above this threshold responded. With TLGcum below 1360 g, 100% of the patient responded, compared with 37% of patients whose TLGcum was above this threshold (p < 0.05). Conventional prognostic factors failed to predict response
Lim et al. [33]	24	Prospective	DLBCL 11, MCL 6, Marginal zone B-cell lymphoma 5, FL 2	Contrast-enhanced PET/CT scan before RIT and at 1 month after RIT in relapsed or refractory B-cell non-Hodgkin's lymphomas, stage I/II 7, stage III/IV 17	^{131}I-rituximab	SUVmax	Tumor size	4/24 patients survived. High SUVmax (SUVmax threshold 7.4 for PFS and 15.3 for OS) in a pretreatment scan was found to be related to poorer OS and PFS (p = 0.04 and 0.02, respectively). SUVmax and tumor size determined by a pretreatment FDG PET/CT result as significant predictors of OS in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma treated by RIT

SUVmax maximum standardized uptake value, *SPECT/CT* single-photon emission computerized tomography, *PFS* progression free survival, *OS* overall survival, *FL* follicular lymphoma, *MALT* mucosa-associated lymphoid tissue, *MCL* mantle cell lymphoma, *DLCBL* diffuse large B-cell lymphoma, *R-CHOP* rituximab; cyclophosphamide; doxorubicin; and prednisone, *ECOG PS* Eastern Oncology Group performance status, *ASCT* autologous stem cell transplantation, *DLBCL R-ICE* rituximab: ifosfamide; carboplatin; and etoposide, *IPI* International Prognostic Index, *BM* bone marrow, *VOI* volume of interest, *CR* complete remission, *PR* partial remission, *SUVbw* SUVbody weight, *SD* stable disease, *PD* progressive disease, *LVol* lesion volume, *TLG* total lesion glycolysis, *TLGcum* cumulative TLG, *TVol* sum of all LVol, *IWC* International Workshop Criteria

[a]32 of whom completed R-ICE and ^{90}Y-ibritumomab tiuxetan-BEAM

and the complementary or combined value of other imaging and biochemical biomarkers. Eight studies in 254 patients evaluated the role of FDG PET as predictor of response in patients submitted to RIT. All patients were retrospectively enrolled with the exception of patients included in the studies carried out by Lim et al. [33] and Hertzberg et al. [28].

Seven studies evaluated the role of FDG PET as well as of other clinical biomarkers. In particular, four studies also evaluated the specific relevance of tumor size as assessed by computed tomography (CT).

Lopci and colleagues evaluated 38 relapsed or refractory FL patients submitted to FDG PET before and 3 months after RIT with the aim of evaluating the role of FDG PET before and after treatment with ^{90}Y-IT [31]. Twenty out of 38 patients had a limited disease on baseline FDG PET, 11 patients had nodal findings on both sides of the diaphragm and the remaining 7 patients had both nodal and extra-nodal findings. When disease extent at relapse and response to treatment were compared, higher rate of complete response (75%) was present in patients with limited metabolic active disease, while patients with diffused PET positive nodal and/or extra-nodal findings were more frequently characterized by partial response or progressive disease (66%) [31]. Prognostic value of post-induction and pre-RIT PET was at least partially addressed in a large study more generally aiming to establish whether treatment intensification with R-ICE chemotherapy (rituximab, ifosfamide, carboplatin, and etoposide) followed by ^{90}Y-ibritumomab tiuxetan-BEAM (BCNU, etoposide, cytarabine, and melphalan) can improve 2 years progression-free survival in high-risk diffuse large B-cell lymphoma patients positive to interim PET scan after 4 cycles of R-CHOP-14 [28]. Patients received 4 cycles of R-CHOP-14, followed by a centrally-reviewed PET performed at day 17–20 of cycle 4 and assessed according to International Harmonisation Project criteria. Among the 143 patients undergoing interim PET, 42 (29%) were PET positive and 32 of them completed R-ICE and ^{90}Y-IT BEAM. However, at a median follow up of 35 months, the 2-year PFS for PET-positive patients was 67%, a rate similar to that for PET-negative patients treated with R-CHOP-14 while overall survival was 78% and 88% respectively. Only in a further exploratory analysis, PFS and OS were markedly superior for PET-positive Deauville score 4 versus score 5. Therefore, the authors concluded that diffuse large B-cell lymphoma patients PET-positive after 4 cycles of R-CHOP-14 and who switched to R-ICE and ^{90}Y-ibritumomab tiuxetan-BEAM could achieve favorable survival outcomes similar to those for PET-negative R-CHOP-14-treated patients [28]. The specific role of PET-based semiquantitative measures has also been tested. Lim and colleagues prospectively enrolled twenty-four patients treated with unlabeled rituximab and a therapeutic activity (median 7.3 GBq) of ^{131}I-rituximab [29]. Contrast-enhanced FDG

PET/CT scans were performed before and 1 month after RIT. Tumor sizes and SUVmax were measured and high baseline SUVmax was found to be related with poorer overall (OS) and progression-free survival (PSF). Furthermore, a large tumor size in pretreatment scan was associated with poorer OS but not with PFS. Finally, in multivariate analyses, a high SUVmax, a large tumor size in a pretreatment scan and diffuse large B-cell lymphoma histology were significantly associated with poorer OS [33].

The value of FDG as prognostic factor in NHL patients treated with RIT has also been evaluated in multicenter studies. In an Italian multicenter study, FDG PET was the only independent pre-RIT biomarker surviving at multivariate analysis and predicting PFS while all the other prognostic factors including age, gender, time from diagnosis to RIT, number of previous treatments, disease extent before RIT did not show significant correlation with response to treatment [30].

Similarly, Grgic et al carried out a multicenter evaluation to prove the feasibility of the multicenter web-based data collection and to preliminary explore imaging findings and prediction of therapy response in patients with FL [29]. They retrospectively analyzed and correlated clinical and imaging data (CT and FDG PET) before and after RIT as documented by the RIT-Network. Evaluation of treatment response was done on both patient- and lesion-basis. Every measurable lesion was analyzed in terms of SUVmax and volume (PET and CT) response. Uni- and multivariate model were used to identify RIT efficacy predictors. A total of 159 lesions were measured. In the multivariate model lesion volume, the total and maximum lesion volume were predictors for response (CR + PR) [29]. When focusing on lesional CR, small lesions volume at baseline and their metabolism were identified as prognostic predictors thus suggesting that FDG PET may also predict the likelihood of response to RIT. Cazaentre et al. retrospectively enrolled 35 patients with NHL who had undergone FDG PET prior to RIT with either ^{90}Y- IT or ^{90}Y-epratuzumab tetraxetan. Four functional variables were measured for each tumour lesion in a given patient (SUVmax and SUVmean, functional lesion volume (LVol) and TLG) while for each patient, highest SUVmax and SUVmean, cumulative TLG (TLGcum) and the sum of all LVol (TVol) were computed [32]. Predictive value on the response [complete or partial response according to International Workshop Criteria (IWC)] to RIT was compared with those of conventional prognostic factors. In particular, conventional prognostic evaluation included, age, histological type, Ann Arbor stage, performance status according to ECOG (Eastern Cooperative Oncology Group), international prognostic indexes, LDH, and the presence of bone marrow involvement. The sum of the products of the two longest perpendicular diameters as defined by IWG criteria and the diameter of the largest lesion on pre-RIT CT

scan were also considered. A total of 154 lesions were analyzed. Nineteen patients (54%) responded to RIT according to IWC. In patients treated with ^{90}Y-IT, response rate was 54% in patients with a SUVmax < 20 g/ml, and 75% both in patients with a TVol < 100 ml or a TLGcum < 1060 g, while no patient above these thresholds responded. The response rate was 93% for patients with SUVmax < 15 g/ml while no patient above this threshold responded. All patients with TLGcum below 1360 g responded, compared with only 37% of patients whose TLGcum was above this threshold. By contrast, conventional prognostic factors failed to predict response and authors concluded that pre-therapy FDG PET functional parameters such as SUVmax and TLG may help predicting more accurate response to single agent Yttrium-90 based RIT [32]. Similarly, Hanaoka and colleagues evaluated both tumor accumulation and heterogeneity of ^{111}In-ibritumomab tiuxetan and tumor accumulation of FDG and compared them to the tumor response in B-cell non-Hodgkin's lymphoma patients treated with ^{90}Y-IT [22]. Sixteen patients were enrolled in this retrospective study. On pretherapeutic FDG PET/CT images, SUVmax was measured. Percentage of the injected dose per gram (%ID/g) and SUVmax of ^{111}In-ibritumomab tiuxetan were also measured at 48 h after its administration. The skewness and kurtosis of the voxel distribution were calculated to evaluate the intratumoral heterogeneity of tumor accumulation. Moreover, cumulative SUV-volume histograms describing the percentage of the total tumor volume above the percentage thresholds of pretherapeutic FDG and ^{111}In-ibritumomab tiuxetan SUVmax were calculated as a further intratumoral heterogeneity index [22]. Forty-two lesions were analyzed and classified into responders and non-responders on lesion-by-lesion basis on post-therapeutic CT images. This study reported a positive correlation between the FDG SUVmax and accumulation of ^{111}In-ibritumomab tiuxetan in lesions. A significant difference in pretherapeutic FDG SUVmax was observed between responders and non-responders, while no significant difference in ^{111}In-ibritumomab tiuxetan SUVmax was observed between the two groups. Accordingly,

authors concluded that pretherapeutic FDG accumulation was predictive of the tumor response to ^{90}Y-IT. The heterogeneity of the intratumoral distribution rather than the absolute level of ^{111}In-ibritumomab tiuxetan was correlated with the tumor response as skewness of ^{111}In-ibritumomab tiuxetan images was significantly different in responders and non-responders [22]. Finally, in a recent study including 34 patients with relapsed indolent lymphoma treated with 90Y-IT monotherapy, predictive value of clinical data as well as CT and FDG PET were retrospectively assessed [27]. In univariate analysis, tumor long axis diameter ≤ 2.5 cm, SUVmax ≤ 6.5, localized disease, normal levels of serum soluble interleukin-2 receptor, and the number of involved nodal sites ≤ 3 immediately prior to ^{90}Y-IT were associated with median PFS greater than 6 years [27]. Of note, in multivariate analysis, only tumor long-axis diameter ≤ 2.5 cm and SUVmax ≤ 6.5 affected PFS. Accordingly, authors concluded that ^{90}Y-IT treatment should be especially considered for patients with indolent lymphoma in first relapse who have tumor long-axis diameter ≤ 2.5 cm and SUVmax ≤ 6.5 [27]. A summary of FDG PET-based parameters already evaluated in studies in patients with different lymphoma subtypes candidates to RIT is reported in Table 2. Two representative examples of baseline and post-therapy FDG PET showing homogeneous and heterogeneous response to RIT are shown in Fig. 1 and 2. In both cases, post-therapy FDG PET was performed 12 weeks after therapy. However, it should be noted that a potential further decline in tumor SUVmax between 12 and 24 weeks in absence of additional therapy has been previously reported thus suggesting the potential usefulness of a more delayed response assessment [34]. More recently, early evaluation 6 weeks after therapy has also been proposed for response assessment and post-therapy prognostic stratification after RIT [35].

Future perspectives

The identification of FDG PET-based variables able to predict response to RIT might be of interest also for the

Table 2 Baseline FDG PET-based parameters potential predictors of response in different NHL subtypes before radioimmunotherapy

PET parameter	Lymphoma subtypes
SUVmax	CD20-positive B-cell non-Hodgkin FL; Indolent lymphoma; DLCBL; MALT; MCL; Marginal zone B-cell lymphoma
SUVmean	B-cell non-Hodgkin lymphoma (DLBCL, FL, MALT, MCL)
Metabolic tumor volume	CD20-positive B-cell non-Hodgkin FL; DLBCL; MALT; MCL
Total lesion glycolysis	B-cell non-Hodgkin lymphoma (DLBCL, FL, MALT, MCL)
Pre-treatment Deauville score	High-risk DLBCL
PET-based diffuse versus limited disease	CD20-positive B-cell non-Hodgkin FL
Heterogeneity indices (FDG uptake)	CD20-positive B-cell non-Hodgkin FL

SUVmax and mean maximum and average standardized uptake value, *FL* follicular lymphoma, *MALT* mucosa-associated lymphoid tissue, *MCL* mantle cell lymphoma, *DLCBL* diffuse large B-cell lymphoma

Fig. 1 Representative example of a homogeneous response to radio-immunotherapy (RIT) in patients with follicular NHL with progressive disease after rituximab and chemotherapy. Pre-RIT FDG PET scan **a** shows highly FDG-avid bilateral cervical, axillary and upper mediastinal lymph nodes (SUVmax 5). Post-RIT FDG PET scan, **b** (performed 12 weeks after therapy) demonstrates complete resolution of abnormal metabolic activity in all sites of disease despite the persistence of measurable lymph nodes (i.e. red arrow shows a subcentimetric non-FDG avid lymph node in the left axilla)


Fig. 2 Representative example of heterogeneous response to radio-immunotherapy (RIT) in a patients with follicular NHL presenting with progressive disease after salvage chemotherapy. Pre-RIT FDG PET scan **a** shows a highly FDG-avid abdominal bulky lesion (SUVmax 12). Post-RIT FDG PET (performed 12 weeks after therapy), **b** demonstrates a residual mass with markedly reduced uptake with respect to baselines scan. However, the residual mass is characterized by a relatively heterogeneous response with some small hot-spots still showing an uptake higher with respect to the uptake of the liver (Deauville score 4)

selection of patients for treatment with new (not yet registered) RIT compounds which could be available in the next future. In fact, despite the underuse of RIT, several new radiolabeled compounds for RIT have been proposed in preclinical models as well as in patients with lymphoma. In particular, epratuzumab is a humanized antibody targeting CD22, known to be highly expressed in most types of lymphoma [36]. This antibody has been labeled with Yttrium-90 and has been used for the treatment of aggressive NHL with 53% of patients showing an objective response [36]. In addition to CD20 and CD22, other biomarkers been investigated as targets for RIT in lymphoma are CD37 [37], CD38 [38], CD25 [39], CXCR4 [40], the human leukocyte antigen DR (HLA-DR) [41] and CD45 [42]. Finally the possibility to administer RIT compounds based on the use of α-particle-emitting radionuclides with their high linear energy transfer (LET) combined with a short path length in tissue, it is a further important emerging opportunity [43].

Conclusions

The literature on the predictive role of FDG PET in NHL patients treated with RIT is still based on studies involving small groups of patients which in the vast majority of cases are retrospectively recruited. Despite these methodological issues, patients- and lesion-based analyses seem to suggest a relevant prognostic role of both morphological (CT) and metabolic imaging (PET). As a matter of fact, it has already been demonstrated that tumor bulk affects PFS and OS. In fact, pre-RIT bulky sites are significantly at the higher risk for disease recurrence and appear to be the first sites of recurrence after RIT [44, 45]. Tumor burden not superior to 5-7 cm [46–48], is significantly associated with higher OS, PFS and CR rate after RIT. As in other context, also in the framework of NHL treated with RIT, evaluation of tumor metabolism seem to provide a further and different window on tumor behavior and responsiveness to therapy. In fact both SUVmax and TLG demonstrated to act as independent predictor of response to 90Y-IT. However emerging PET-based parameters such as MTV and TLG were analyzed in very few studies. Similarly, while the predictive role of tumor extension and volume as assessed by CT have a well-established prognostic role, the spin-off of the specific weight of metabolic active tumor burden is not trivial and not clearly possible from published studies. Similarly, it is still not possible to specifically define the best PET-based predictor and the identification of reproducible cut-offs (i.e. for SUVmax, MTV or TLG) in NHL treated with RIT is still a very complex issue. In this framework, the availability of FDG PET in patients included in already completed clinical trials might be of interest and could be used for new analyses in homogeneous groups of patients thus allowing to more

deeply disclose the role of specific PET-based parameters as prognostic indicator in NHL patients candidate to RIT. In recent years, FOLL12 study (EUDRACT 2012-003170-60) a multicenter, phase III, randomized study aiming to evaluate the efficacy of a response-adapted strategy in patients with advanced-stage Follicular Lymphoma has been promoted and carried out by Italian centers belonging to the "Fondazione Italiana Linfomi" (FIL). In this study, the experimental arm is based on FDG PET and molecular minimal residual disease (MRD) results. In these patients, a de-intensified treatment is reserved to MRD- and PET-negative cases while a consolidation with radio-immunotherapy is performed in patients still PET-positive after induction and a pre-emptive therapy is adopted for PET-negative but MRD-positive patients. FOLL12 has now completed recruitment of 810 patients [49]. Once analyses addressing primary and secondary endpoints will be published, the same homogenous group of patients might be used also to specifically assess the prognostic value of baseline FDG PET in patients treated with RIT based on the study design.

Compliance with ethical standards

References

1. Kapadia NS, Engles JM, Wahl RL (2008) In vitro evaluation of radioprotective and radiosensitizing effects of rituximab. J Nucl Med 49(4):674–678
2. Dillman RO (2002) Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 20(16):3545–3557
3. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A et al (1999) Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17(12):3793–3803
4. Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL et al (2002) Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99(12):4336–4342
5. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN et al (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20(15):3262–3269

6. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R et al (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20(10):2453–2463

7. Rizzieri D (2016) Zevalin® (ibritumomab tiuxetan): after more than a decade of treatment experience, what have we learned? Crit Rev Oncol Hematol 105:5–17

8. Mondello P, Cuzzocrea S, Navarra M, Mian M (2016) ^{90}Y-ibritumomab tiuxetan: a nearly forgotten opportunity. Oncotarget 7(7):7597–7609

9. Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L et al (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377(9759):42–51

10. Lindén O, Tennvall J, Cavallin-Ståhl E, Darte L, Garkavij M, Lindner K (1999) Radioimmunotherapy using ^{131}I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas. J Clin Cancer Res 5(10 Suppl):3287s–3291s

11. Hohloch K, Lankeit HK, Zinzani PL, Scholz CW, Lorsbach M, Windemuth-Kieselbach C et al (2014) Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network. Eur J Nucl Med Mol Imaging 41(8):1585–1592

12. White CA, Halpern SE, Parker BA, Miller RA, Hupf HB, Shawler DL et al (1996) Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies. Blood 87(9):3640–3649

13. Buchegger F, Press OW (2011) Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma. EJNMMI Res 1(1):7

14. Multani P (2002) Development of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma. Int J Hematol 76(5):401–410

15. Illidge TM (2010) Radioimmunotherapy of lymphoma: a treatment approach ahead of its time or past its sell-by date. J Clin Oncol 28:2944–2946

16. Schaefer NG, Ma J, Huang P, Buchanan J, Wahl RL (2010) Radioimmunotherapy in non-Hodgkin lymphoma: opinions of US medical oncologists and hematologists. J Nucl Med 51(6):987–994

17. Garber K (2007) Users fear that lymphoma drugs will disappear. J Natl Cancer Inst 99(7):498–499

18. Press OW (2008) Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas. J Clin Oncol 26(32):5147–5150

19. Eskian M, Khorasanizadeh M, Kraeber-Bodere F, Rezaei N (2016) Radioimmunotherapy in non-Hodgkin lymphoma: prediction and assessment of response. Crit Rev Oncol Hematol 107:182–189

20. Conti PS, White C, Pieslor P, Molina A, Aussie J, Foster P (2005) The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry. J Nucl Med 46(11):1812–1818

21. Kaneko K, Choi I, Nakagawa M, Shinozaki K, Uike N (2014) Does tumoral (111)In-ibritumomab accumulation correlate with therapeutic effect and outcome in relapsed or refractory low-grade B-cell lymphoma patients undergoing (90)Y-ibritumomab radioimmunotherapy? Eur Radiol 24(12):3191–3198

22. Hanaoka K, Hosono M, Tatsumi Y, Ishii K, Im SW, Tsuchiya N et al (2015) Heterogeneity of intratumoral (111)In-ibritumomab tiuxetan and (18)F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin's lymphoma. EJNMMI Res 5:10

23. Nowosinska E, Chan PS, Buscombe JR (2018) Use of 18F FDG PET and the short temporal response of Hodgkin's disease to RIT. World J Nucl Med 17(3):171–177

24. Takahashi M, Momose T, Koyama K, Ichikawa M, Kurokawa M, Ohtomo K (2014) Dynamic metabolic changes during the first 3 months after 90Y-ibritumomab tiuxetan radioimmunotherapy. Sci World J 2014:368947

25. Storto G, De Renzo A, Pellegrino T, Perna F, De Falco T, Erra P et al (2010) Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Radiology 254(1):245–252

26. Gregory SA (2003) Selecting patients for treatment with 90Y ibritumomab tiuxetan (Zevalin). Semin Oncol 30(Suppl. 17):17–22

27. Tsukamoto N, Yokohama A, Higuchi T, Mitsui T, Koiso H, Takizawa M et al (2019) Tumor long-axis diameter and SUVmax predict long-term responders in 90Y-ibritumomab tiuxetan monotherapy. Int J Hematol 109(1):91–97

28. Hertzberg M, Gandhi MK, Trotman J, Butcher B, Taper J, Johnston A et al (2017) Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. Haematologica 102(2):356–363

29. Grgic A, Nestle U, Scheidhauer K, Puskas C, Ballek E, Hohloch K (2011) Retrospective web-based multicenter evaluation of ^{18}F-FDG-PET and CT derived predictive factors. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan in follicular non Hodgkin's lymphoma. Nuklearmedizin 50(1):39–47

30. Lopci E, Santi I, Derenzini E, Fonti C, Savelli G, Bertagna F et al (2010) FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study. Ann Oncol 21(9):1877–1883

31. Lopci E, Santi I, Tani M, Maffione AM, Montini G, Castellucci P et al (2010) FDG PET and ^{90}Y-ibritumomab tiuxetan in patients with follicular lymphoma. Q J Nucl Med Mol Imaging 54(4):436–441

32. Cazaentre T, Morschhauser F, Vermandel M, Betrouni N, Prangère T, Steinling M et al (2010) Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 37(3):494–504

33. Lim I, Park JY, Kang HJ, Hwang JP, Lee SS, Kim KM et al (2013) Prognostic significance of pretreatment ^{18}F-FDG PET/CT in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma treated by radioimmunotherapy using ^{131}I-rituximab. Acta Haematol 130(2):74–82

34. Jacene HA, Filice R, Kasecamp W, Wahl RL (2009) 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. J Nucl Med 50(1):8–17

35. Kitajima K, Okada M, Kashiwagi T, Yoshihara K, Tokugawa T, Sawada A et al (2019) Early evaluation of tumor response to (90) Y-ibritumomab radioimmunotherapy in relapsed/refractory B cell non-Hodgkin lymphoma: what is the optimal timing for FDG-PET/CT? Eur Radiol. https://doi.org/10.1007/s00330-019-06134-7

36. Witzig TE, Tomblyn MB, Misleh JG, Kio EA, Sharkey RM, Wegener WA et al (2014) Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. Haematologica 99(11):1738–1745

37. Blakkisrud J, Løndalen A, Martinsen AC, Dahle J, Holtedahl JE, Bach-Gansmo T et al (2017) Tumor-absorbed dose for non-Hodgkin lymphoma patients treated with the anti-CD37 antibody

radionuclide conjugate ^{177}Lu-Lilotomab satetraxetan. J Nucl Med 58(1):48–54

38. Green DJ, O'Steen S, Lin Y, Comstock ML, Kenoyer AL, Hamlin DK et al (2017) CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies. Blood 131:611–662

39. Janik JE, Morris JC, O'Mahony D, Pittaluga S, Jaffe ES, Redon CE et al (2015) 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma. Proc Natl Acad Sci USA 112(42):13045–13050

40. Lapa C, Hänscheid H, Kircher M, Schirbel A, Wunderlich G, Werner RA et al (2019) Feasibility of CXCR43-directed radioligand therapy in advanced diffuse large B-cell lymphoma. J Nucl Med 60(1):60–64

41. Pagel JM, Orgun N, Hamlin DK, Wilbur DS, Gooley TA et al (2009) A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. Blood 113(20):4903–4913

42. Orozco JJ, Kenoyer A, Balkin ER, Gooley TA, Hamlin DK, Wilbur DS et al (2016) Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment. Blood 127(3):352–359

43. Seidl C (2014) Radioimmunotherapy with α-particle-emitting radionuclides. Immunotherapy 6(4):431–458

44. Gokhale AS, Mayadev J, Pohlman B, Macklis RM (2005) Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy. Int J Radiat Oncol Biol Phys 63(1):194–201

45. Rajguru S, Kristinsdottir T, Eickhoff J, Peterson C, Meyer CM, Traynor AM et al (2014) Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study. Clin Adv Hematol Oncol 12(8):509–515

46. Ibatici A, Pica GM, Nati S, Vitolo U, Botto B, Ciochetto C et al (2014) Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study. Br J Haematol 164(5):710–716

47. Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW et al (2007) Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 109(9):1804–1810

48. Illidge TM, McKenzie HS, Mayes S, Bates A, Davies AJ, Pettengell R et al (2016) Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. Br J Haematol 173(2):274–282

49. Trotman J, Barrington SF, Meignan M (2019) Does end-of-treatment FDG-PET improve outcomes in follicular lymphoma? Authors' reply. PET investigators from the GALLIUM study. Lancet Oncol 20(1):e5